2021-02-14T09:54:45.650+01:00 – M.D.
The vaccine against Covid-19, developed by Sanofi in partnership with the American Translate Bio, will not be ready until next year. A new setback for the French pharmaceutical group. Initially, its release was scheduled for the end of 2021. “This vaccine will not be ready this year, but it could prove useful later, especially if the fight against the variants were to continue”, explains Sanofi CEO Paul Hudson in an interview with Sunday newspaper, without giving more details. Clinical trials of this vaccine, which uses the same technology as those of Pfizer-BioNTech and Moderna, are due to begin this quarter, he said.
The French laboratory had already announced in December that its recombinant protein vaccine candidate, which it is developing this time with the British laboratory GSK, would not be available before the fourth quarter of 2021. Provisional data from a clinical trial have shown unsatisfactory results for older people. “We would have liked to be ready sooner. But in order to design the best possible vaccine, no compromise on its effectiveness was possible, especially with regard to the oldest populations”, explains to JDD the CEO of Sanofi. “We are working to make it available in the last quarter”, he promises.
Some see it as a failure, but was it necessary to stand idly by?– Paul Hudson, CEO of Sanofi
In the meantime, Sanofi has announced that it will produce in the second half of the year the vaccine against Covid-19 developed by the American-German alliance Pfizer-BioNTech. The French laboratory will package 100 million doses from next July in a factory in Frankfurt, Germany. “Some see it as a failure, but was it necessary to stand idly by? This decision will save lives! We are the first to do so and, for now, we are doing more than many others”, underlines Paul Hudson, in reaction to the “bashing” which the laboratory has been facing since it announced a delay for its main candidate vaccine against Covid-19.
I hope you are in health and well.
I offer you important instructions regarding this article
- The article has been translated based on the content of the source link below these instructions
If there is any problem related to the content, copyright, correctness of the information contained in this article, or If there are errors in the language, please leave a report below the article. or contact us via email [email protected]. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!
- We only want readers to access information quickly and easily using other multilingual content, rather than information only available in a specific language.
- We always respect the copyright of the author’s content and always include the original link of the source article, and if the author does not agree, leave the report below the article, the article will be edited or deleted at the author’s request. Thank you so much! Warm greetings!